BIPHETAMINE 12.5
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIPHETAMINE 12.5 is an extended-release oral capsule approved in 1955 as an NDA product by UCB Pharma. The mechanism of action and specific indications are not currently documented in available data. This is a legacy product with a long market history.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect downsizing of brand support teams and shift to generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero active job postings linked to BIPHETAMINE 12.5 reflects its legacy status and impending LOE. Career opportunities are primarily in managing generic transition and maximizing final years of exclusivity rather than growth or expansion.
Brand ManagerField Sales Representative
Worked on BIPHETAMINE 12.5 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.